Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Emergent Biosolutions ( (EBS) ) has provided an update.
On June 23, 2025, Emergent BioSolutions announced a $62.4 million contract modification with the Administration for Strategic Preparedness and Response (ASPR) for the supply of BAT®, a botulism antitoxin. This contract modification underscores the U.S. government’s commitment to stockpiling medical countermeasures and highlights Emergent’s role in strengthening global emergency preparedness and public health protection.
The most recent analyst rating on (EBS) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Emergent Biosolutions stock, see the EBS Stock Forecast page.
Spark’s Take on EBS Stock
According to Spark, TipRanks’ AI Analyst, EBS is a Neutral.
Emergent Biosolutions is facing significant financial challenges with declining revenues and profitability, which heavily weigh on its overall score. Technical indicators are mixed but slightly positive, and while the earnings call highlighted some improvements, the valuation remains poor. Corporate events present both legal challenges and growth opportunities.
To see Spark’s full report on EBS stock, click here.
More about Emergent Biosolutions
Emergent BioSolutions is a company focused on delivering protective and life-saving solutions for health threats such as smallpox, mpox, botulism, Ebola, anthrax, and opioid overdose emergencies.
Average Trading Volume: 1,220,898
Technical Sentiment Signal: Sell
Current Market Cap: $337.6M
See more insights into EBS stock on TipRanks’ Stock Analysis page.